| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
|
AIDS
|
2010
|
5.85
|
|
2
|
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
|
Ann Intern Med
|
2011
|
5.35
|
|
3
|
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
|
AIDS
|
2007
|
4.31
|
|
4
|
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.
|
BMJ
|
2011
|
3.72
|
|
5
|
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
|
Lancet
|
2004
|
3.59
|
|
6
|
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
|
J Infect Dis
|
2010
|
3.30
|
|
7
|
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
|
AIDS
|
2006
|
3.23
|
|
8
|
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
|
Int J Epidemiol
|
2011
|
2.80
|
|
9
|
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
|
J Infect
|
2013
|
2.66
|
|
10
|
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.
|
BMJ
|
2005
|
2.51
|
|
11
|
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
|
AIDS
|
2009
|
2.50
|
|
12
|
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
|
PLoS Med
|
2013
|
2.49
|
|
13
|
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
|
AIDS
|
2007
|
2.47
|
|
14
|
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
|
AIDS
|
2005
|
2.45
|
|
15
|
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
|
AIDS
|
2014
|
2.27
|
|
16
|
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.
|
HIV Med
|
2012
|
2.24
|
|
17
|
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).
|
HIV Med
|
2014
|
2.18
|
|
18
|
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
|
Clin Infect Dis
|
2009
|
1.96
|
|
19
|
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
|
Ann Neurol
|
2008
|
1.90
|
|
20
|
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
|
Clin Infect Dis
|
2009
|
1.86
|
|
21
|
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach.
|
AIDS
|
2010
|
1.82
|
|
22
|
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.
|
Int J Epidemiol
|
2002
|
1.79
|
|
23
|
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study.
|
BMJ
|
2012
|
1.71
|
|
24
|
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
|
PLoS Med
|
2010
|
1.65
|
|
25
|
Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients.
|
Am J Kidney Dis
|
2012
|
1.62
|
|
26
|
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.
|
Epidemiology
|
2011
|
1.59
|
|
27
|
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.
|
J Infect Dis
|
2005
|
1.46
|
|
28
|
Renal tubular disease in the era of combination antiretroviral therapy.
|
AIDS
|
2015
|
1.44
|
|
29
|
The changing pattern of bronchoscopy in an HIV-infected population.
|
Chest
|
2002
|
1.42
|
|
30
|
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
|
Antivir Ther
|
2008
|
1.41
|
|
31
|
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
|
Euro Surveill
|
2015
|
1.29
|
|
32
|
Data linkage reduces loss to follow-up in an observational HIV cohort study.
|
J Clin Epidemiol
|
2010
|
1.26
|
|
33
|
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
|
Clin Infect Dis
|
2012
|
1.25
|
|
34
|
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
|
Clin Infect Dis
|
2014
|
1.25
|
|
35
|
Definition and epidemiology of late presentation in Europe.
|
Antivir Ther
|
2010
|
1.23
|
|
36
|
Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.
|
J Cereb Blood Flow Metab
|
2004
|
1.21
|
|
37
|
Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.
|
Gastroenterology
|
2012
|
1.13
|
|
38
|
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
|
AIDS
|
2012
|
1.11
|
|
39
|
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.
|
AIDS
|
2010
|
1.07
|
|
40
|
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
|
41
|
Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons.
|
Sex Transm Dis
|
2006
|
1.03
|
|
42
|
Natural history of HIV-control since seroconversion.
|
AIDS
|
2013
|
1.02
|
|
43
|
Designing and interpreting HIV noninferiority trials in naive and experienced patients.
|
AIDS
|
2008
|
1.02
|
|
44
|
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
|
AIDS
|
2008
|
1.02
|
|
45
|
Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.
|
Curr Opin HIV AIDS
|
2010
|
1.01
|
|
46
|
Decline of CD4⁺ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.
|
AIDS
|
2011
|
1.01
|
|
47
|
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.
|
Antivir Ther
|
2010
|
1.00
|
|
48
|
Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters.
|
J Acquir Immune Defic Syndr
|
2003
|
0.99
|
|
49
|
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).
|
J Acquir Immune Defic Syndr
|
2010
|
0.99
|
|
50
|
Risk of tuberculosis following HIV seroconversion in high-income countries.
|
Thorax
|
2012
|
0.96
|
|
51
|
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.
|
AIDS
|
2010
|
0.95
|
|
52
|
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
|
J Infect Dis
|
2004
|
0.94
|
|
53
|
Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients.
|
Nephrol Dial Transplant
|
2011
|
0.94
|
|
54
|
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.
|
PLoS One
|
2011
|
0.91
|
|
55
|
Clinical epidemiology of HIV-associated end-stage renal failure in the UK.
|
AIDS
|
2009
|
0.91
|
|
56
|
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.
|
AIDS
|
2011
|
0.89
|
|
57
|
Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
|
Clin Trials
|
2010
|
0.89
|
|
58
|
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
|
AIDS
|
2014
|
0.87
|
|
59
|
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study.
|
AIDS
|
2005
|
0.86
|
|
60
|
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
|
J Acquir Immune Defic Syndr
|
2015
|
0.86
|
|
61
|
How likely is environmental or patient cross-contamination of Chlamydia trachomatis DNA to lead to false positive results in patients attending our clinic?
|
Sex Transm Infect
|
2012
|
0.84
|
|
62
|
The impact of HIV drug resistance testing on changes to treatment.
|
AIDS
|
2011
|
0.84
|
|
63
|
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance.
|
BMC Med Res Methodol
|
2012
|
0.83
|
|
64
|
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
|
Clin Infect Dis
|
2015
|
0.83
|
|
65
|
Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons.
|
AIDS
|
2016
|
0.82
|
|
66
|
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.
|
AIDS
|
2012
|
0.82
|
|
67
|
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.
|
AIDS
|
2013
|
0.82
|
|
68
|
Higher vaginal pH is associated with Chlamydia trachomatis infection in women: a prospective case-controlled study.
|
Int J STD AIDS
|
2005
|
0.82
|
|
69
|
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
|
J Infect Dis
|
2009
|
0.81
|
|
70
|
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.
|
AIDS
|
2015
|
0.81
|
|
71
|
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.
|
J Antimicrob Chemother
|
2013
|
0.81
|
|
72
|
Factors influencing lopinavir and atazanavir plasma concentration.
|
J Antimicrob Chemother
|
2010
|
0.80
|
|
73
|
Differences in presentation and follow-up between HIV-1 antibody positive teenagers and adults: the need for a more focused approach to care?
|
AIDS
|
2003
|
0.78
|
|
74
|
Early initiation of treatment for HIV infection.
|
Lancet
|
2010
|
0.78
|
|
75
|
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
|
J Acquir Immune Defic Syndr
|
2016
|
0.78
|
|
76
|
Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption.
|
J Acquir Immune Defic Syndr
|
2009
|
0.77
|
|
77
|
Is HIV Painful? An Epidemiologic Study of the Prevalence and Risk Factors for Pain in HIV-infected Patients.
|
Clin J Pain
|
2014
|
0.77
|
|
78
|
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.
|
BMC Nephrol
|
2014
|
0.77
|
|
79
|
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
|
AIDS
|
2015
|
0.76
|
|
80
|
Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.
|
AIDS
|
2015
|
0.76
|
|
81
|
Sociodemography of genital co-infection with Neisseria gonorrhoeae and Chlamydia trachomatis in Coventry, UK.
|
Int J STD AIDS
|
2005
|
0.76
|
|
82
|
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?
|
J Infect Dis
|
2012
|
0.76
|
|
83
|
Biomarkers to monitor safety in people on art and risk of mortality.
|
J Acquir Immune Defic Syndr
|
2012
|
0.76
|
|
84
|
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women.
|
BMC Infect Dis
|
2014
|
0.75
|
|
85
|
Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
86
|
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.
|
AIDS
|
2016
|
0.75
|
|
87
|
Early assessment of anti-HIV drug efficacy.
|
Lancet
|
2002
|
0.75
|
|
88
|
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
89
|
Hepatitis B, hepatitis C and mortality among HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
|
90
|
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals.
|
AIDS
|
2016
|
0.75
|
|
91
|
Measurement of retinal vessels as a biomarker of cerebrovascular ageing in older HIV positive men compared to controls.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
92
|
Definition of loss of virological response in trials of antiretroviral drugs.
|
AIDS
|
2003
|
0.75
|
|
93
|
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
|
94
|
Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
95
|
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.
|
Antivir Ther
|
2008
|
0.75
|
|
96
|
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
|
97
|
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.
|
J Acquir Immune Defic Syndr
|
2009
|
0.75
|